Precision Biosciences
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
Genome Editing Firm Precision BioSciences Prices $126.4M IPO
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
Pressure Biosciences Expands Sales, Marketing
The company has contracted with EKG Sales Associates for life science lead generation and hired two new sales directors.
Precision BioSciences Raises $25.6M in Series A Financing
The North Carolina-based firm plans to use the money to continue development of its Arcus genome editing platform.
Precision Bio, Nova Synthetix to Collaborate on Ricin-Free Castor Plant Development
NEW YORK (GenomeWeb News) – Precision BioSciences and Nova Synthetix today announced a deal for the use of each other's technologies to generate "non-GM," ricin-free castor plants.